Compare Mesoblast Limited (MESO) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Newmont Corporation — how do they compare? Mesoblast Limited trades at $16.68 (market cap $2.21B), while Newmont Corporation trades at $118.38 (market cap $123.50B). The key difference: Newmont Corporation is far larger — about 55.9× Mesoblast Limited's market cap, and Newmont Corporation pays a 0.89% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | NEM | |
|---|---|---|
Market Cap | $2.21B | $123.50B |
Sector | Technology | Basic Materials |
52-Week High | $20.96 | $131.95 |
52-Week Low | $12.88 | $67.38 |
Enterprise Value | $2.21B | $120.09B |
Dividend Yield | — | 0.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Newmont Corporation (NEM) trades at $117.26, up 3.79% over 24 hours, near its 52-week high. The stock exhibits strong bullish technical signals and robust fundamentals, with revenue growing to $22.67 billion in 2025 and net income reaching $7.09 billion. Recent news highlights the resolution of a Nevada joint venture dispute with Barrick Mining, providing operational clarity.
The outlook for NEM remains positive, supported by strong earnings beats, a favorable analyst consensus, and rising gold prices. Key risks include gold price volatility and execution of production targets. The consensus price target of $133.00 suggests upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
